Bellicum Pharmaceuticals, Inc. (BLCM)

Market Cap	10.42M
Revenue (ttm)	1.50M
Net Income (ttm)	-16.25M
Shares Out	8.61M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	735
Open	1.13
Previous Close	1.24
Day's Range	1.11 - 1.25
52-Week Range	0.60 - 2.20
Beta	1.38
Analysts	Buy
Price Target	5.10 (+311.29%)
Earnings Date	Mar 23, 2023

About BLCM

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trial...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 18, 2014
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: BLCM

Financial Performance

In 2021, BLCM's revenue was $6.20 million, an increase of 1140.00% compared to the previous year's $500,000. Losses were -$9.71 million, 25.7% more than in 2020.

Analyst Forecast

According to 7 analysts, the average rating for BLCM stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 311.29% from the latest price.

Price Target

$5.1

(311.29% upside)

Analyst Consensus: Buy